Volume 24 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(1): 79-82
WANG Baojia, DI Jiamei, XIE Weinan, DAI Rong, HAN Shu, YUAN Ling. The efficacy of roxadustat versus rHuEPO in treating renal anemia and its impact on cardiac function in patients with chronic kidney disease undergoing peritoneal dialysis[J]. Chinese Journal of General Practice, 2026, 24(1): 79-82. doi: 10.16766/j.cnki.issn.1674-4152.004334
Citation: WANG Baojia, DI Jiamei, XIE Weinan, DAI Rong, HAN Shu, YUAN Ling. The efficacy of roxadustat versus rHuEPO in treating renal anemia and its impact on cardiac function in patients with chronic kidney disease undergoing peritoneal dialysis[J]. Chinese Journal of General Practice, 2026, 24(1): 79-82. doi: 10.16766/j.cnki.issn.1674-4152.004334
shu

The efficacy of roxadustat versus rHuEPO in treating renal anemia and its impact on cardiac function in patients with chronic kidney disease undergoing peritoneal dialysis

doi: 10.16766/j.cnki.issn.1674-4152.004334
  • 1.

    Graduate School of Bengbu Medical University, Bengbu, Anhui 233000, China

Funds:

 AHWJ2023A10030

  • Received Date: 2025-01-23
    Available Online: 2026-04-01
    Abstract
  •   Objective  To compare the clinical efficacy of roxadustat and recombinant human erythropoietin (rHuEPO) in the treatment of renal anemia in peritoneal dialysis patients with chronic kidney disease and its effect on cardiac markers.  Methods  A retrospective analysis was performed for 40 patients with renal anemia who received regular peritoneal dialysis from September 2022 to September 2023 in the Renal Dialysis Center of the First Affiliated Hospital of Anhui University of Science and Technology, including 20 patients treated with roxadustat (observation group) and 20 patients treated with rHuEPO (control group). The efficacy of anemia and its effect on cardiac indexes were compared between the two groups.  Results  After adjusting for the pretreatment levels of each index by covariance analysis, the observation group demonstrated significantly higher levels of hemoglobin (Hb) compared to the control group [(115.45±12.94) g/L vs. (99.25±13.11) g/L, F=21.233, P < 0.001] after treatment. The levels of total cholesterol (TC), left anterior posterior diameter (LAD), and interventricular septal thickness (IVST) in the observation group were lower than those in the control group after treatment, the difference was statistically significant (P < 0.05).  Conclusion  Roxadustat treatment can improve the anemia of patients more effectively, and can improve iron metabolism and lipid metabolism in patients, with less negative impact on cardiac function, and the effect is better than rHuEPO.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733. doi: 10.1016/S0140-6736(20)30045-3
    [2]
    金德伟, 陶敏, 马晓燕, 等. 慢性肾脏病非透析患者脑钠肽前体异常的危险因素分析[J]. 中华全科医学, 2021, 19(8): 1314-1317. doi: 10.16766/j.cnki.issn.1674-4152.002049

    JIN D W, TAO M, MA X Y, et al. Risk factors for brain natriuretic peptide precursor abnormalities in non-dialysis patients with chronic kidney disease[J]. Chinese Journal of General Practice, 2021, 19(8): 1314-1317. doi: 10.16766/j.cnki.issn.1674-4152.002049
    [3]
    CHENG S Q, ZHOU T T, YU L, et al. Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis[J]. Front Med (Lausanne), 2023, 10: 1166024. DOI: 10.3389/fmed.2023.1166024.
    [4]
    LI Z L, TU Y, LIU B C. Treatment of renal anemia with roxadustat: advantages and achievement[J]. Kidney Dis (Basel), 2020, 6(2): 65-73. doi: 10.1159/000504850
    [5]
    LIU J, YANG F, WAHEED Y, et al. The role of roxadustat in chronic kidney disease patients complicated with anemia[J]. Korean J Intern Med, 2023, 38(2): 147-156. doi: 10.3904/kjim.2022.318
    [6]
    SONG J, CHEN X J, ZHOU L S, et al. Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients[J]. J Int Med Res, 2023, 51(10): 3000605231204475. DOI: 10.1177/03000605231204475.
    [7]
    陈薇, 张梦洁, 冯荣, 等. 低氧诱导因子在心血管疾病中的研究进展[J]. 中国动脉硬化杂志, 2024, 32(1): 72-78.

    CHEN W, ZHANG M J, FENG R, et al. Research progress of hypoxia-inducible factors in cardiovascular diseases[J]. Chinese Journal of Arteriosclerosis, 2024, 32(1): 72-78.
    [8]
    吴雪兵, 敖华, 王晟, 等. 罗沙司他联合重组人促红细胞生成素对铁蛋白正常和过载维持性血液透析患者贫血纠正的效果[J]. 贵州医科大学学报, 2023, 48(2): 188-192.

    WU X B, AO H, WANG S, et al. Effect of roxadustat combined with recombinant human erythropoietin on anemia correction in patients with ferritin normal and overload maintenance hemodialysis[J]. Journal of Guizhou Medical University, 2023, 48(2): 188-192.
    [9]
    SOFUE T, NAKAGAWA N, KANDA E, et al. Prevalence of anemia in patients with chronic Kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB)[J]. PLoS One, 2020, 15(7): e0236132. DOI: 10.1371/journal.pone.0236132.
    [10]
    BI S H, CHEN W, WU J S, et al. The history of peritoneal dialysis in China: past, present and future trends[J]. Ren Fail, 2021, 43(1): 1601-1608. doi: 10.1080/0886022X.2021.2011316
    [11]
    张军, 方利, 郑小玲, 等. 透析模式对终末期肾病患者心血管结局影响的研究进展[J]. 重庆医学, 2023, 52(21): 3314-3318.

    ZHANG J, FANG L, ZHENG X L, et al. Research progress on the effect of dialysis mode on cardiovascular outcomes in patients with end-stage renal disease[J]. Chongqing Medicine, 2023, 52(21): 3314-3318.
    [12]
    黄泽慧, 刘英莉. 透析前患者教育在终末期肾脏疾病患者管理中的相关研究进展[J]. 中华全科医学, 2020, 18(10): 1725-1728, 1749. doi: 10.16766/j.cnki.issn.1674-4152.001604

    HUANG Z H, LIU Y L. Research progress on pre-dialysis patient education in the management of patients with end-stage renal disease[J]. Chinese Journal of General Practice, 2020, 18(10): 1725-1728, 1749. doi: 10.16766/j.cnki.issn.1674-4152.001604
    [13]
    RAWEE P, EISENGA M F. Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?[J]. Ned Tijdschr Geneeskd, 2023, 167: D7706.
    [14]
    胡菂菂, 李恩就, 刘娜, 等. 罗沙司他对维持性血液透析患者肾性贫血的疗效及铁、脂代谢的影响[J]. 中国医学创新, 2023, 20(14): 50-55.

    HU D D, LI E J, LIU N, et al. Effect of roxadustat on renal anemia and iron and lipid metabolism in patients on maintenance hemodialysis[J]. Chinese Journal of Medical Innovation, 2023, 20(14): 50-55.
    [15]
    HIRAI K, KANEKO S, MINATO S, et al. Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease[J]. Front Med (Lausanne), 2023, 10: 1071342. DOI: 10.3389/fmed.2023.1071342.
    [16]
    邢艳芳, 秦军建, 高皛磊, 等. 罗沙司他与重组人促红细胞生成素治疗肾性贫血疗效观察[J]. 广州医科大学学报, 2022, 50(3): 58-62.

    XING Y F, QIN J J, GAO X L, et al. Efficacy of roxadustat and recombinant human erythropoietin in the treatment of renal anemia[J]. Journal of Guangzhou Medical University, 2022, 50(3): 58-62.
    [17]
    SIGNORE P E, GUO G, WEI Z, et al. A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats[J]. PLoS One, 2021, 16(8): e0255022. DOI: 10.1371/journal.pone.0255022.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (21) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return